The North American Menopause Society Annual Meeting

While estrogen therapy may not be the best option for all women in menopause, there is an effort underway to help educate patients and providers alike as to how best to approach this topic to provide the best results possible.

There are several products on the market designed to help patients manage the symptoms associated with menopause. New research was recently presented on one option which does not include progesterone and what that means for care.

At The North American Menopause Society 27th Annual Meeting (NAMS) in Orlando, Florida, Janet Carpenter, PhD, RN, Indiana University discussed her latest research in nonhomonal alternatives for women experiencing hot flashes including a clinical hypnosis protocol.

At The North American Menopause Society 27th Annual meeting (NAMS), Holly Thomas, MD, MS, University of Pittsburgh, discussed her program of research mainly focuses on how sex changes for women as they move through midlife and into older age.

At The North American Menopause Society 27th Annual Meeting (NAMS), Rebecca Thurston, PhD, University of Pittsburgh, discussed her research on the relationship between sleep and cardiovascular disease in menopause patients.

As Peter Schnatz, DO, Reading Health System, completes his term as President of NAMS, he reflected on the initial goals he'd had before assuming his position. His primary initiative was to bring the best care they could to menopausal women. Schnatz said they'd been working really hard on reopening the conversation of the use and utilization of hormonal therapy.

Peter Schnatz, DO, Reading Health System, current President of The North American Menopause Society (NAMS), spoke about his presidential address, which discussed breast arterial calcification (BAC) and the association with risk factors and atheroscleratic cardiovascular disease.

There is limited data in this population, but some research says that women shouldn't be starting the therapy after the age of 60. However, hormone therapies offer bone protection, which opens the door discussion on usage.

Hadine, Joffe, MD, MSc, explained at The North American Menopause Society 27th Annual Meeting (NAMS), that their research validates there's a biological basis for these symptoms and that these are the brains' responses to hormone changes and the symptom manifestations of those hormone changes.

At The North American Menopause Society 27th Annual Meeting (NAMS), Hadine Joffe, MD, MSc, Brigham and Women's Hospital explained that she always has her patients use sleep hygiene, and that there are some really key strategies that has no side effects.

Do osteoporosis medications impact sexual function? That's what researchers aimed to find in a study presented at The North American Menopause Society 27th Annual Meeting (NAMS 2016) in Orlando, Florida.

Hadine Joffe, MD, MSc, Brigham and Women's Hospital has been trying to figure out the common menopause symptoms and how to treat them. As a psychiatrist and considering her vested interest in the brain manifestations of hormone changes, some of the symptoms she focuses on are hot flashes, sleep, and mood.

Since vitamin D plays a key role in bone mineralization, and older people tend to need more bone support, researchers looked at how providing supplementation impacted postmenopausal women.

Previous research has found that hypertension and cardiovascular health is linked to the age that a woman goes through natural menopause. A study led by researchers from the Netherlands aimed to find if blood pressure has an impact.

Adding to the seemingly endless number of reasons for keeping weight under control, a new analysis out of Brazil shows that obesity impacts menopausal symptoms.

“TX-004HR was designed to rapidly and effectively treat all symptoms of vulvar and vaginal atrophy (VVA) without increasing serum E2 levels,” a collaborative team of researchers began in a new phase 3 study.

Geography, age, and time are factors that contribute to the likelihood that a woman is being treated for menopause, according to new research out of Pfizer Inc.

Hot flashes are no stranger to 75% of women in menopause and the symptoms are severe for 15% of them.

Do sexual concerns hurt the quality of romantic relationships? Many would probably nod. But data on older women shows changes over the years.

Merck & Co., Inc. has spent years on clinical trials in hopes of submitting odanacatib to the US Food and Drug Administration (FDA) for the treatment of osteoporosis. Unfortunately, the process ends here.